Minimal and Null Predictive Effects for the Most Popular Blood Biomarkers of Cardiovascular Disease
出版年份 2012 全文链接
标题
Minimal and Null Predictive Effects for the Most Popular Blood Biomarkers of Cardiovascular Disease
作者
关键词
-
出版物
CIRCULATION RESEARCH
Volume 110, Issue 5, Pages 658-662
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2012-03-03
DOI
10.1161/res.0b013e31824da8ad
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Problems With Risk Reclassification Methods for Evaluating Prediction Models
- (2011) M. S. Pepe AMERICAN JOURNAL OF EPIDEMIOLOGY
- Risk factors and interventions with statistically significant tiny effects
- (2011) G. C. Siontis et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Commentary: Reporting standards are needed for evaluations of risk reclassification
- (2011) M. S. Pepe et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Use of reclassification for assessment of improved prediction: an empirical evaluation
- (2011) Ioanna Tzoulaki et al. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
- Comparison of Effect Sizes Associated With Biomarkers Reported in Highly Cited Individual Articles and in Subsequent Meta-analyses
- (2011) John P. A. Ioannidis JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials
- (2011) Michael V Holmes et al. LANCET
- Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
- (2011) Georg B. Ehret et al. NATURE
- Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease
- (2011) Heribert Schunkert et al. NATURE GENETICS
- Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis
- (2011) David S. Wald et al. PLoS One
- 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
- (2010) et al. CIRCULATION
- Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study
- (2010) Michael Preuss et al. Circulation-Cardiovascular Genetics
- Biological, clinical and population relevance of 95 loci for blood lipids
- (2010) Tanya M. Teslovich et al. NATURE
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers
- (2010) Michael J. Pencina et al. STATISTICS IN MEDICINE
- B-Type Natriuretic Peptides and Cardiovascular Risk
- (2009) Emanuele Di Angelantonio et al. CIRCULATION
- Criteria for Evaluation of Novel Markers of Cardiovascular Risk
- (2009) Mark A. Hlatky et al. CIRCULATION
- Genetic Loci Associated With C-Reactive Protein Levels and Risk of Coronary Heart Disease
- (2009) Paul Elliott JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Assessment of Claims of Improved Prediction Beyond the Framingham Risk Score
- (2009) Ioanna Tzoulaki JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Major Lipids, Apolipoproteins, and Risk of Vascular Disease
- (2009) The Emerging Risk Factors Collaboration* JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Homocysteine Level and Coronary Heart Disease Incidence: A Systematic Review and Meta-analysis
- (2009) Linda L. Humphrey et al. MAYO CLINIC PROCEEDINGS
- C-Reactive Protein and Parental History Improve Global Cardiovascular Risk Prediction
- (2008) Paul M Ridker et al. CIRCULATION
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Why Current Publication Practices May Distort Science
- (2008) Neal S Young et al. PLOS MEDICINE
- Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review
- (2008) John Danesh et al. PLOS MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started